Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides
Summary
USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.
What changed
USPTO issued Patent US12600959B2 to Halozyme, Inc. for modified PH20 hyaluronidase polypeptides exhibiting increased stability and/or activity. The patent covers compositions, formulations, and methods of use. The grant date is April 14, 2026, with 15 claims allowed.
Affected parties including pharmaceutical companies, biotech firms, and manufacturers developing hyaluronidase-based therapeutics should monitor this patent for Freedom to Operate considerations. The patent may affect competitive landscape for enzyme-based drug delivery technologies.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PH20 polypeptide variants, formulations and uses thereof
Grant US12600959B2 Kind: B2 Apr 14, 2026
Assignee
Halozyme, Inc.
Inventors
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Abstract
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
CPC Classifications
C12N 9/2474 A61P 35/00 A61K 9/0019 A61K 38/28 A61K 38/47 A61K 45/06 A61K 47/10 A61K 38/00 C07K 14/47 C07K 2319/30 C12Q 1/134 C12Y 302/01035 Y02A 50/30 G01N 2333/926 G01N 2333/928
Filing Date
2025-03-05
Application No.
19071345
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.